




CYBERDYNE



**Consolidated Financial Result Briefing
for the fiscal year ended March 31, 2024**

**CYBERDYNE, Inc.
May 15, 2024**

Consolidated financial statements

FY2024 - Consolidated Results Summary (IFRS)

(Unit : Millions of yen)

	FY2022	FY2023	+/-	YoY
Revenue	3,289	4,354	+1,065	+32.4%
Operating profit	-1,145	-2,018	-873	—
Profit before tax	53	-1,141	-1,194	—
Profit attributable to owners of parent	-298	-1,476	-1,178	—
EBITDA [☆]	-1,005	-1,177	-172	—

Revenue

4,354 Million
YoY +1,065 million (+32%)

- Increase from rental outside Japan +121 Million
- Increase from treatment service in US RISE Group etc. +361 Million
- Increase from acquisition of new business area such as German mobility company +582 Million

Operating profit

-2,018 Million
YoY -873 Million

- Increase from rental +137 Million
- Initial investment in U.S. and European subsidiaries -350 Million
- One-time losses due to impairment of good will -660 Million

* Operating profit without this one-time losses
-1,358 Million
YoY -213 Million

Profit before tax

-1,141 Million
YoY -1,194 Million

- Increase of operating loss -873 Million
- Finance income/expenses and gain/loss related to CEJ Fund -321 Million

☆ EBITDA = Operating profit + Depreciation and amortization ± Other income and expenses

Consolidated financial results (IFRS)

Performance trends

【Q4 results】 Sales +24% (QoQ comparison)

(Unit : Millions of Yen)

	FY2022	FY2023					Quarter on Quarter		Year on Year	
	Q4	Q1	Q2	Q3	Q4	Q1-Q4	+/-	+/- %	+/-	+/- %
Revenue	915	1,045	1,058	1,115	1,135	4,354	+20	+1.8%	+220	+24.0%
Cost of sales	440	480	480	517	484	1,961	-33	-6.3%	+44	+10.1%
Gross profit	475	566	579	598	651	2,393	+53	+8.8%	+176	+37.0%
R&D Expenses	241	174	180	163	360	877	+197	+120.9%	+119	+49.6%
Other SG&A	757	766	757	771	958	3,251	+187	+24.3%	+201	+26.5%
Other income/ expenses	127	67	-651	49	252	-282	+203	+411.2%	+125	+98.4%
Operating profit	-396	-308	-1,008	-287	-415	-2,018	-129	-	-19	-
Finance income/ expenses	434	363	-12	-106	-184	61	-78	-	-618	-142.4%
Other	-97	712	74	6	24	816	+18	+272.6%	+121	-
Profit before tax	-59	767	-947	-386	-575	-1,141	-189	-	-516	-
Profit attributable to owner of the parent	-366	330	-933	-349	-525	-1,476	-176	-	-159	-
EBITDA	-488	-212	-194	-177	-595	-1,177	-418	-	-107	-

Consolidated financial results: Revenue/Operating profit (Margin)

Operating profit from rental of products 818 Million (Operating profit margin 46%)

(Unit : Millions of Yen)

		FY2022 Q1-Q4	FY2023 Q1-Q4	+/-	+/- %
Product rental	Revenue Operating profit (Margin) ☆	1,640 744 (45%)	1,762 818 (46%)	+121 +74	+7% +10%
Treatment service	Revenue Operating profit (Margin) ☆	1,285 -310 (-24%)	1,646 -552 (-34%)	+361 -242	+28% -
New business expansion	Revenue Operating profit (Margin) ☆	364 -161 (-44%)	946 -197 (-21%)	+582 -35	+160% -
RD expenses and Head office expenses ☆☆	Adjusted amount	-1,418	-2,087	-670	-
Consolidated total (IFRS)	Revenue Operating profit (Margin)	3,289 -1,145 (-35%)	4,354 -2,018 (-46%)	+1,065 -873	+32% -

☆ Operating income by business segment is the amount of profit or loss, which is revenue minus operating expenses, for each business.

☆☆ RD expenses and head office expenses, are adjustment amount of R&D expenses, head office administrative expenses, other income and expenses, etc.

Without one-time expense of (660M), -1,427M

- Rental of product: Rental income from the Group's product (include income from sold products)
- Treatment service: Income from treatment at the Group's rehabilitation facilities (including Robocare)
- New business expansion: Revenue from new business area of the Group (subsidiary company in mobility and sleep apps)

Rental revenue by each products

Overseas product rental sales increased by 190M YoY (+30%)


Usage	Product classification	Japan	Outside Japan	Total
Cybernetics Treatment (Functional improvement/ regeneration)	HAL Lower Limb Type (Medical)	333 (325)	517 +40% (369)	850 (694)
	HAL Lower Limb Type (non-medical)	163 (179)	-	163 (179)
	HAL Single Joint Type	90 (116)	100 (82)	190 (198)
Care and for well-being	HAL Lumbar Type for Well-being	114 (162)	95 (113)	209 (275)
Labor Support	HAL Lumbar Type for Labor Support	46 (65)	-	46 (65)
	Mobility Robot (CL02 etc.)	139 (89)	-	139 (89)
Other (Acoustic X and other products)		60 (78)	103 (62)	164 (140)
Total		946 (1,015)	816 +30% (626)	1,762 (1,640)

(Unit : Millions of Yen)

Top : FY2023 Q1-Q4
(Bottom : FY2022 Q1-Q4)

Consolidated financial results (IFRS) by geographical region

Significant increase of oversea sale +1,155M (53% to 67% of total revenue)



Americas: North, Central and South America
 EMEA : Europe, the Middle East and Africa
 APAC : Asia-Pacific * Revenue from Japan is stated separately

Ref) Consolidated financial results (IFRS) by geographical regions and type of transaction

Significant increase in overseas revenue from each type of transaction

(Unit : Millions of Yen)

FY2023 Q1-Q4 (FY2022 - Q1-Q4)	Japan	Americas	EMEA	APAC	Total
Rental of products	946 (1,015) -7%	68 (51) +34%	280 (205) +36%	468 (370) +27%	1,762 (1,640) +7%
Treatment service	137 (169) -19%	1,453 (1,051) +38%	55 (65) -14%	-	1,646 (1,285) +28%
New businesses	373 (364) +3%	-	573 (-) +236%	-	946 (364) +160%
Total	1,457 (1,547) -6%	1,521 (1,102) +38%	908 (270) +236%	468 (370) +27%	4,354 (3,289) +32%


Outline of the business

Realization of Techno-peer Support Society

A future society where people and technology coexists, cooperates and mutually support each other


For wide variety of people faced with health, physical function, cognitive and psychological problems

A safe and secure society (well-being society) where people of all generations can increase their independence, freedom and solve various problems in their lives



→ Create “Cybernics Industry”, a new industry that follows Robot and IT Industry

Cybernetics: Fuses and combines humans, AI-Robots and Information Systems



***Cybernetics:** Science and technology in cutting-edge areas that combine different fields such as brain/neuroscience, physiology, artificial intelligence (AI), robotics, information technology (IT), psychology, economy and innovation with a focus on Human, AI-robots and Information Systems to realize the fusion of bio/medical technologies and AI, robotics and information technologies.

(Reference)
The Cabinet Office's FIRST, ImPACT, and SIP programs address Cybernetics as pioneering cutting-edge innovative science and technology areas

Business in the integrated space of “Human” + “Cyber/Physical Space”

Improving the well-being of seniors and people with disability

HAL Single Joint Type
Flexible product that can be used for intensive rehabilitation of elbow, wrist and ankle joints

HAL Lumbar Type for Well-being
A product that supports both caregivers and care-receivers.

Cybernics Space
Fusion of “Human” + “Cyber/Physical Space”

Cleaning Robot
Autonomous robot that takes cleaning and disinfection to the next level

Transportation Robot
Autonomous robot that can carry heavy loads on its own

Cyin for Living Support
Helps communication of patients in severe condition

Improving the well-being through supporting and supervising solutions

HAL Single Joint Type
Flexible product that can be used for intensive rehabilitation of elbow, wrist and ankle joints

HAL Lumbar Type for Well-being
A product that supports both caregivers and care-receivers.

Cybernics Space
Fusion of “Human” + “Cyber/Physical Space”

Cleaning Robot
Autonomous robot that takes cleaning and disinfection to the next level

Transportation Robot
Autonomous robot that can carry heavy loads on its own

Cyin for Living Support
Helps communication of patients in severe condition

Towards the 5th Industrial Revolutions! “Human”+”Cyber/Physical Space” HCPS Fusion Technology Cybernics Industry that will follow Robot and IT Industry

Prevention/Early Detection/Medical&Healthcare

Improving well-being of seniors and people with disability

Improving well-being through supervising and live support solutions

Work support and improving efficiency through AI automation

Prevention, early detection and medical/healthcare

HAL Single Joint Type
Flexible product that can be used for intensive rehabilitation of elbow, wrist and ankle joints

HAL Lumbar Type for Well-being
A product that supports both caregivers and care-receivers.

Cybernics Space
Fusion of “Human” + “Cyber/Physical Space”

Cleaning Robot
Autonomous robot that takes cleaning and disinfection to the next level

Transportation Robot
Autonomous robot that can carry heavy loads on its own

Cyin for Living Support
Helps communication of patients in severe condition

Work support and improving efficiency through AI automation

HAL Single Joint Type
Flexible product that can be used for intensive rehabilitation of elbow, wrist and ankle joints

HAL Lumbar Type for Well-being
A product that supports both caregivers and care-receivers.

Cybernics Space
Fusion of “Human” + “Cyber/Physical Space”

Cleaning Robot
Autonomous robot that takes cleaning and disinfection to the next level

Transportation Robot
Autonomous robot that can carry heavy loads on its own

Cyin for Living Support
Helps communication of patients in severe condition

【Medical】 Global Dissemination of Cybernics Treatment

Wearable Cyborg HAL : Cybernics Treatment that induces functional regeneration


Signals from a person's brain nerve system are processed by signal processing and artificial intelligence in real-time, HAL moves as if it were a part of the person's own body according to the person's intention

Medical

HAL

hybrid assistive limb

Technology is worth nothing
unless it is used in real life



- 1) HAL obtains information related to the brain nerve and muscles from the peripheral part of the body
- 2) HAL synchronizes with the wearer's intentions and functions according to the intention
- 3) Forms an interactive bio-feedback loop to induce improvement in the body-nerve and muscles systems, achieving the goal of the Cybernics Treatment

【Medical】 Insurance reimbursement for Cybernics Treatment

Increased insurance points after confirming safety and efficacy during 5 years of post-marketing surveillance

- ◆ Excerpts from the Proposal to Evaluate the Medical Technology (why it should be reevaluated) submitted by the Japanese Society of Neurological Therapeutics – Translated by CYBERDYNE

“During 5 years of post-marketing surveillance, the medical technology produced significant improvement of physical function towards slowly progressive neuromuscular disease, **which are intractable diseases with no established treatment methods that are effective**. The medical effect observed was unheard of by any existing treatment methods, including pharmaceuticals approved for these diseases. Due to the progressive nature of these intractable diseases, research on the natural course of the disease suggest a gradual decline of motor functions. However, when this medical technology was utilized repeatedly over a long duration of 3.5 years, an opposite trend was suggested, and motor function was maintained/improved. Furthermore, the medical technology did not increase the destruction of the patient’s muscles. The CK value in the blood** was actually in the declining trend, which is medically noteworthy. **Thus, it was suggested that medical technology is a safe treatment method for progressive neuromuscular patients.** The medical technology should no longer be regarded as a treatment method to support gait exercises. **It should be reevaluated as a new treatment method to activate the loop of the patient’s brain-nerve systems.**”



Added to items not covered by the DPC comprehensive evaluation (items calculated at piece rate)!

Increased reimbursement points (40,000 yen for the first 9 sessions and 20,000 yen for the following sessions) are realized!

【Medical】 Cybarnics Treatment (functional improvement/rehabilitation treatment)

Cybarnics Treatment: Developed as innovative method utilizing HAL for treating brain-nerve-musculoskeletal disorders



HAL Lumbar Type

HAL Single Joint Type

HAL Lower Limb Type



*The treatment services operated by the Group are classified as “service sales” and “rental sales” in cases where products are rented based on rental contract

Global dissemination of Cybernics and reinforcing collaboration ①

INTERNATIONAL CONFERENCE on CYBERNICS HAL 2023

2023.10.13 Kuala Lumpur Malaysia



Strengthening international collaboration by bringing together clinicians, researchers, and other experts from around the world who work with Cybernics

Global dissemination of Cybernics and reinforcing collaboration ②

2024.1.12 Hannover Germany

Cybernics & Neurobionics Summit 2024 (Jointly hosted by International Neuroscience Institute)

Gathering the world's leading pioneers in cutting-edge developments in Cybernics and neurobionics




Joint hosts
 Dr. Madjid Samii (center) - Founder of INI, President of INI
 Dr. Amir Samii (right) - Vice President of INI

Progress of approval by the U.S. FDA

US FDA becomes to first to clear HAL Small Model and Cerebral Palsy (2024/5/7)

*Above 12 years old

Use image of HAL Small Model*




Applicable height
150~190cm

Applicable height
100~150cm

**Conventional
model**

**Small
Model**



*Product used in this image differs from the medical version

© Okayama Robocare Center

Development pipeline (1)

1) Medical HAL (Lower Limb Type) : Clinical trials etc.

As of May 15 2024

Target disease		Product Development	Clinical Trial (Exploratory)	Clinical Trial (Validation)	Application/examination	Approval (public health insurance in Japan)	Marketing (Post-marketing surveillance)	Public health insurance	Current status
Neuromuscular Disease (8 types of disease such as ALS and muscular dystrophy)									FY2022 revision (DPC calculation) Planning for public health insurance Planning for insurance reimbursement
Spinal related disease (2 diseases virus and hereditary)									Public health insurance approved Applying for expansion of target diseases Obtained medical device clearance
Spinal Cord Injury									Communicating with regulators Preparing trial towards public health insurance (Germany) Planning for insurance reimbursement
Stroke									Preparing for additional clinical trial Planning for public health insurance Planning for insurance reimbursement
Cerebral Palsy									Investigator-initiated clinical trial
Multiple Sclerosis									

2023/10
MHLW approves insurance reimbursement
 • HTLV-1 Associated Myelopathy (HAM)
 • Hereditary spastic paraplegia

2024/5 !!
US FDA clears three additional diseases
 • Cerebral Palsy*
 • HTLV-1 Associated Myelopathy (HAM)
 • Hereditary Spastic Paraplegia



*Above 12 years old

Public workers
 Compensation
 insurance (Germany)

Development pipeline (2)

2) Medical HAL (Lumbar Type) : Clinical trials etc.





As of May 15 2024

Target disease	Product Development	Clinical Trial (Exploratory)	Clinical Trial (Validation)	Application/examination	Approval (public health insurance in Japan)	Marketing (Post-marketing surveillance)	Public health insurance	Current status
Parkinsons Disease 							Currently designing a protocol for clinical trials while confirming efficacy through pilot studies	

*Topics : Started working on parkinsons disease, a disease with over nine million patients world wide

3) Medical HAL (Single Joint Type)

As of May 15 2024

Target disease	Product Development	Clinical Trial (Exploratory)	Clinical Trial (Validation)	Application/examination	Approval (public health insurance in Japan)	Marketing (Post-marketing surveillance)	Public health insurance	Current status
Brain-nerve (e.g. stroke) 							<div style="border: 1px solid red; padding: 2px;">Public Health Insurance</div>	Equipment for increasing exercise load Planning for insurance reimbursement Planning for insurance reimbursement
Orthopedics (e.g. Post knee joint replacement) 								Planning for insurance reimbursement Planning for insurance reimbursement Planning for insurance reimbursement

Medical device approval for Medical HAL Lower Limb Type

Expansion of cleared diseases in USA (Disease/Size)

As of May 15, 2024

		Stroke	Spinal Cord Injury	Neuromuscular Disease*	Other diseases	Small size
Japan		(Preparing for additional trial)	(Communicating with regulators)	Approved	<ul style="list-style-type: none"> • HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia 	(application in progress)
USA		Approved	Approved	Approved	<ul style="list-style-type: none"> • Cerebral palsy • HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia 	Approved
EMEA	Europe	Approved	Approved	Approved		(application in progress)
	Türkiye	Approved	Approved	Approved		
	Saudi Arabia	Approved	Approved	Approved		
APAC	Malaysia	Approved	Approved	Approved		
	Indonesia	Approved	Approved	Approved		
	Thailand	Approved	Approved	Approved		
	Singapore	Approved	Approved	Approved		
	India	Approved	Approved	Approved		
	Taiwan	(application in progress)	Approved	(application in progress)		
	Australia	Approved	Approved	Approved		

*Spinal muscular atrophy, spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, distal muscular dystrophy, inclusion body myositis, congenital myopathy, muscular dystrophy

Global dissemination of Medical HAL/Cybernetics Treatment

Available in over 20 countries and regions



Cyberdyne Care Robotics (Germany)



Brooks Rehabilitation (US Florida)



RISE Healthcare Group (USA California)

EMEA Base
Cyberdyne Care Robotics GmbH (Germany)



Coopselios (Italy)



PERKESO - REHABILITATION CENTRE MELALA (Malaysia)

APAC Base
CYBERDYNE MALAYSIA SDN. BHD.



Singapore General Hospital (Singapore)

Americas Base
CYBERDYNE USA INC.

EMEA : Europe, Middle East and Africa

Development of Cybernics Treatment through Rise Healthcare



- ◆ Strong business in LA • San Diego
- ◆ Commenced fee-based service from 2023 (out-of-pocket+insurance hybrid treatment)
- ◆ No. treatment sessions increased 2.4 times, even though fee-based service started*
- ◆ Top3 users are stroke, Parkinson's disease and spinal cord injury patients
- ◆ 76% referred by doctors/patient-to-patient/patient associations


*Performance from January to December



Accelerate business further in light of approval of HAL small model, and expansion of indications for cerebral palsy, etc.

Social implementation of Cybernics Treatment (Malaysia)

Collaboration with Malaysian government-affiliated organizations to promote Cybernics Treatment




Social implementation of Cybernics Treatment (Malaysia)

Provides Cybernics Treatment free for patients due to Public Social Compensation Insurance

SOCSCO(Malaysia Public Social Security Organization)

SOCSCO has four functions: disability pension, survivor's pension, medical coverage and occupational injury coverage, and is compulsory for Malaysian and foreign workers in Malaysia to join the program. It provides medical compensation, disability compensation, funeral benefits, child support and nursing care benefits for illness or injury that occurs while commuting to and from work.

Facilities with HAL (12 facilities)



★ SOCSCO Rehabilitation Center

Socso urged to build three new rehabilitation centres in five years

Bernama
15/01/2024 16:00 MYT

Human Resources Minister Urges Nationwide Expansion of SOCSCO Rehabilitation Centers



<https://www.astroawani.com/berita-malaysia/socso-urged-build-three-new-rehabilitation-centres-five-years-454129>

Social implementation of Cybernics Treatment (Malaysia)

The National Center for Neuro-Robotics and Cybernics, the largest medical complex in Southeast Asia

National Neuro-Robotic and Cybernics Centre



- ✓ Construction underway in Ipoh, Perak, Northern part of Malaysia (Scheduled by the end of 2024)
- ✓ First phase project
 - ✓ 15.6 Hectare (Approx. 3.4 baseball stadiums)
 - ✓ Gross floor area is approximately 86,400 square meters
- ✓ Capable of accommodating 700 patients at any given time



Strategic base for social implementation of Cybernics Industry, such as HAL, Cybernics Products and technologies of other companies that CYBERDYNE invests through C-Startup

https://www.perkeso.gov.my/images/kenyataan_media/2023/190203_-_LAWATAN_MENTERI_SUMBER_MANUSIA_KE_TAPAK_PUSAT_REHABILITASI_PERKESO_PERAK.pdf?TSPD_101_R0=08e2dacd5fab2000f93a5be67765406ad4c598e4e5aedac205dcd286f8c106bc77d7648842ded7a008048fa483143000fbc3f707cd511bf1367c7352c9e10251d84d1723291abc11ccb8adcf6ab4640a6f84d8e56752b87e7c10ac4d5baf7b

Spinal Cord Injury: Clinical Trials by German Insurance Authorities

Clinical trials to be conducted on the premise of German public medical insurance coverage

G-BA (German Federal Joint Committee) decides to conduct clinical trials under the premise of insurance coverage

G-BA approves Cybernics Treatment as the standard of care to be considered for spinal cord injury patients (in accordance with §137eSGB V of the Study Regulations)

G-BA itself decides to conduct a clinical trial (the clinical trial will be covered by public health insurance for Cybernics Treatment in advance).

The results of the clinical trial are expected to be included in the German public medical insurance system.

G-BA Preparing Protocol for Clinical Trials

2023/01 Protocol outline presented

2023/03 Expert hearing held

2023/09 Protocol guideline announced → **Commenced selection of CRO on March 2024**

G-BA (Federal Joint Committee): Organization at the federal level that determines basic benefits, prices, standards, etc. for German insurance treatment.

§137e SGB V (Trial Regulation): A system under which the G-BA conducts its own initiated clinical trials and makes final evaluations of promising treatments that could become the standard of care.

Social implementation of Cybernics Treatment (Italy)

Promoting “Scientific Evidence-Based Rehabilitation Model”

Utilizing 25 units of HAL for treatment of approximately 1,000 stroke and spinal cord injury patients



Key points of collaboration

- ◆ Operates Italian Cybernic Center - Second walk (Within Italy)
- ◆ Cooperation for public health insurance reimbursement in Italy
- ◆ Utilization of Coopselios Network in Asia, Middle East, South America and Africa

- ✓ Social cooperative association established on 1984
- ✓ Service in medical, care and education fields
- ✓ Provides service to approximately 6,500 people daily in 8 areas of Italy
- ✓ Over 3,000 professionals

Healthcare and labor support

【Healthcare】 Neuro HALFIT (Functional Improvement Program)

Program to improve brain-nerve-musculoskeletal function at Robocare Center



HAL Lumbar Type



HAL Single Joint Type




HAL Lower Limb Type



Medical Healthcare Service for Individuals: Neuro HALFIT at Home

Expansion of remote services connecting home and hospitals/facilities through cloud computing

【Integrated Cybernics System】



Robocare Center: Nationwide expansion of *Neuro HALFIT*

Expansion of hubs in the medical healthcare service business for individuals



Available in 18 locations nationwide

【Healthcare】 HAL Lumbar Type care prevention program

Significant improvement in mobility functions (daily activities such as standing, walking, running, sitting) of the elderly

Care prevention program (Kanagawa Mirai MIBYO Cohort Study)

Interim evaluation results of short-term intervention twice a week for a total of 10 sessions




Evaluation item	Before HAL Mean (95%CI)	After HAL Mean (95%CI)	Improvement rate	P-value
10m walk (walking speed m/sec)	1.05 (0.98, 1.12)	1.43 (1.35, 1.51)	36%	<0.001***
Locomotiv 5 check <small>*Signs of motor unit deterioration</small>	8.5 (7.7, 9.3)	4.4 (3.3, 5.4)	93%	<0.001***

Recruited N=80 people (79 participants: Intervention group 40, Control group 39)


Results excluding 2 people n=77 (Average age : 74.7 ± 4.7 years old)

※ ※ [Healthcare] Neuro HALFIT at Home (for individuals in daily lives)

Functional improvement program at home (expands home visit services)



Use image of Neuro HALFIT at Home



HAL is data-linked with the Cyberdyne Cloud, which visualizes biopotential signals that command body movements and posture information, etc. This system enables the wearer to obtain visual feedback and allows the trains to customize a program for each user based on the results of data analysis

*The Home programs are classified as “service sales” and “rental sales” in cases where products are rented based on rental contract

【Labor Support】 HAL Lumbar Type

New HAL Lumbar will be announced soon, making the device light weighted and thinner

Lightest Active type device

Slim design (back free)

Assist walk

Can move around in crouching posture

IoH/IoT device

Wearable Cyborg


Puts on in 10 seconds

Water/dustproof (IEC reg IP54)

- Can be worn for long hours
- **Became even lighter (2.7kg)**
- Can be worn together with safety belts (full body) and air-conditioned clothes
- **Can drive cars while wearing it**
- Can move smoothly to the required venue
- Assists various practical movements
- Visualize workload analysis and operating status! integrated production management
- It moves according to the wearer's intention
- Easy to put on and take off, share with multiple people!
- Can be worn outdoors, even in the rain! **(New model is also waterproof)**



**Lighter !
Thinner !**



【Workplace】 Disinfection/Cleaning Robot CL02

Make office buildings smarter and reduce management costs with advanced technology
Can also be linked with building OS! (Also considering collaboration with major industry players)

Extensive Cleaning ability

- **High-speed autonomous navigation** (Can safely clean at 4km/h to cover massive space in a short time)
- **Massive cleaning area** (Detects wall that is 30m away and covers max 3,000m² with full charge battery)
- **High vacuum performance** (One of the best in the industry)

Can be used for multiple tasks such as disinfection

- **Disinfection agent sprayer** (Disinfects handrails and benches)
- **UV Ray Disinfector** (Set on the bottom of the robot to disinfect floors)
- **Wiper cleaner** (Small sound as it does not use vacuum)
- **Carpet spray & Brushing** (Make carpet long lasting)

Visualizes assigned tasks


- **Dust distribution map** (visualizes result of the task)
- **Navigated route** (to create efficient and effective cleaning plan)

Automatically rides on the elevator

- **Elevator interface unit developed inhouse** (Can connect to elevators developed by multiple vendors)
- **Can work on multiple floors** (Expands the space that can be cleaned)


Cloud linkage

- **“CYCLES” designed for the Robot** (realizes high usability and management)
- **Integration with the base system**




Strategy for growth

Image of growth scenario: Strengthen development areas and business strategies



HCPS fusion technology : Cybernics/Human cooperative robotics

As a commitment to science, technology and innovation, CYBERDYNE participated in the Cabinet Office Strategic Innovation Creation Program (SIP) to strengthen growth strategies




- 1) Application to various living spaces such as houses, facilities, workplaces, etc.
- 2) Utilization of HCPS fusion master/remote control technology (Cybernic master/remote technology) integrated with human information (physiology, body, behavioral cognition, psychology, etc.)
- 3) Non-invasive acquisition and utilization of human information through HCPS fusion human collaborative robotics
- 4) Linking with other related technologies to improve the independence and freedom of seniors and people with mobility problems

Future of medical healthcare and healthy life

Prevention/pre-symptomatic, medicine, rehabilitation/long-term care

Medical/Healthcare/Healthy life




Close coordination, fusion between medical and non-medical field to evolve into comprehensive initiatives

Healthcare monitoring on daily basis with Cyvis

Daily accumulation, analysis, and AI processing of various vital data

- **Cardiac activity**
- **brain activity**
- **body temperature**
- **Body movements**
- **Breathing / SpO2 (optional)**




Check for **arrhythmia** and **atrial fibrillation**
to prevent **myocardial infarction** and **cerebral infarction**
Option to check **breathing conditions** during sleep for early detection of **sleep apnea risk**

- ✓ Developed “Cyvis-2” after trial of “Cyvis-1”
- ✓ “Cyvis-2” submitted medical device application on Apr. 2024 and schedules to commercialize on summer to autumn 2024


【Prevention and early detection】 Ultra small vital sensor Cyvis

Expands remote service that connects households to hospitals and facilities



Cybernics Medical Healthcare System

Prevent, early detect and improve on daily basis (data linkage with Cyberdyne Cloud)




Seamless data linkage between hospitals, facilities, homes, and workplaces with IoH/IoT

Contrast-free, non-invasive, real-time, high-resolution 3D imaging

LED array method (patent held by CYBERDYNE)



Adopted as the cover of Biophotonics, a U.S. industry journal dealing with biophotonics



Peripheral vascular and blood conditions, etc.

Peripheral level examination, which could not be done with conventional imaging equipment, is now possible!


Example of application

- Routine examination and diagnosis of diabetic foot lesions
- Examination of vascular regeneration status by regenerative medicine
- Examination and diagnosis of cancer
- Examination of aging skin, etc.

Currently promoting medical device commercialization as a next-generation medical diagnostic imaging device


【Prevention/early detection】 Acoustic X” photoacoustic imaging system with LED light source

Hospitals with Acoustic X: Various hospitals installed the product for clinical researches



C-Startup : Innovation ecosystem to create Cybernics Industry

Cybernics Industry



C-Startup

Kringle Pharma
2020/12 listed

CureApp

Allm SHAPING HEALTHCARE
2022/6 M&A

CYFUUSE
2022/12 listed

Technical advices
Financial support
Business support

CYBERDYNE

Medical institutions, care facilities, companies, allied partners

University, research institute, government
WEF Centre for 4th Industrial Revolution,
Consortium of cutting-edge medicine in the
21st century
Smart city council etc.,

CYBERDYNE

CEJ Fund (scale of 10 billion)

CYBERDYNE 大和ハウス工業株式会社


SOMPO 損保ジャパン DAIDO 大同生命 MIZUHO みずほ銀行

THK 筑波銀行 global brain MIZUHO みずほキャピタル

2024.3.31 updated

(Ref) Fair value assessment of strategic investment through “C-Startup”

Cumulative investment income 11.4 billion yen vs cumulative investment amount 5.1 billion yen



*Unlisted equity securities are fair valued in accordance with IFRS 9 "Financial Instruments"

**OCI (Other Comprehensive Income): Income not recognized in net profit or loss (PL)

(Reference) Investments in which no valuation differences are currently recognized: 6 companies

(As of March 31, 2024)

Cybernetics Medical Innovation Base: Outline

Reinforcing CYBERDYNE's growth strategy
Accelerate the fusion of bio- and medical-related technologies with AI, robotics, and information technologies

Innovation center based on Cybernetics Technology and regenerative medicine/drug discovery



Life science companies such as C-Startup partners in regenerative medicine and drug discovery move in
New fusion R&D will be promoted!

Cybernetics Medical Innovation Base: Purpose

1) Combined Cybernetics Treatment : Regenerative Medicine and HAL

While "Cybernetics Treatment" using the world's first Wearable Cyborg HAL is becoming a standard treatment for functional improvement and regeneration of human brain nerves and muscles (HAL is already available in 20 countries in Europe, the U.S., Asia, etc.), **further therapeutic effects are expected for severe patients by introducing technology at the cellular level and cell-produced substances.** The Group will promote the systemization of Cybernetics Treatment at this research facility.

2) Combined Cybernetics Treatment : Drug and HAL

After the post-marketing study of "Cybernetics Treatment" using the Wearable Cyborg HAL, **the combination of the latest nucleic acid drugs and HAL** has begun in actual medical practice, and **synergistic effects from the combined therapy of drugs and HAL are hoped for.** CYBERDYNE will promote the systematization of Cybernetics Treatment in cooperation with pharmaceutical companies and the institutions occupying such research facilities.

3) Integration of medical and bio-based technologies with AI, robotics, and information systems

In addition to deploying the Group's **new-generation robotic bioreactor technologies and technologies that integrate medical/biotechnologies with AI, robotics, and information technologies,** the company will provide research facilities to partner companies (**medical/biotechnological companies and start-ups** that can collaborate with the Company) and others to develop new medical technologies and expand the Company's business.

This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.

Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been compiled from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.